Study of the Pathogenesis of Porphyria Cutanea Tarda

Plain-language summary

This study examined how a disease called porphyria cutanea tarda develops. People with well-documented sporadic (Type I) or familial (Type II) porphyria cutanea tarda confirmed by blood, urine, and stool tests could take part. It was carried out as a study with no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

National Center for Research Resources (NCRR)

Start date

11/1/2000

Countries

United States

Related genes

Locations

• Galveston, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

* Well documented sporadic (Type I) or familial (Type II) porphyria cutanea tarda: Increased plasma porphyrins (fluorescence maximum at neutral pH near 617 nm) Increased urinary porphyrins (consisting mostly of uroporphyrin and heptacarboxylporphyrin) Increased isocoproporphyrins in feces
* No other type of porphyria